Jean-Pierre Boissel

TL;DR: A reduction in mortality during the first 6 months with polychemotherapy is shown, although small, and this increase in survival, together with an improved quality of life, suggests that polyChemotherapy should be recommended for patients with non-resectable non small cell lung cancer.

TL;DR: Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis and it remains to be shown in a suitably powered clinical trial whether low molecular weight Heparin reduces the risk of fatal pulmonary embolism compared withHeparin.

TL;DR: In this paper, the average treatment effect in both sexes and to determine whether available data show significant differences in treatment effect between women and men was quantified by a subgroup meta-analysis of individual patient data according to sex.

TL;DR: An open-label, randomized trial comparing a short oral anticoagulant course with a long course of therapy after a first episode of venous thromboembolism, which found the 2 treatment regimens had an equivalent effect.

TL;DR: Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in the treatment of venous thrombosis, however, these results remain to be confirmed by using clinical outcomes in suitably powered clinical trials.